Application of FeTMPyP in preparation of medicine for relieving ovarian toxicity

By using FeTMPyP to target nitrification stress, the ovarian toxicity caused by the combined exposure of microcystis toxin and nitrite was alleviated, ovarian dysfunction and reproductive health were improved, and the fertility of mice was restored.

CN120241742AActive Publication Date: 2025-07-04ZHENGZHOU UNIV

Patent Information

Application Number
CN202510663224.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-22
Publication Date
2025-07-04
Estimated Expiration
2045-05-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively alleviate the ovarian toxicity caused by the combined exposure of microcystis toxins (MCs) and nitrites (NaNO2), especially the follicle barrier damage and reproductive endocrine dysfunction caused by nitrification stress on ovarian cells.

Method used

Iron (III)tetra(4-methylpyridinyl)porphyrin (FeTMPyP) is used as an intervention agent to target nitrification stress, and ovarian toxicity is alleviated by decomposing peroxynitrite (ONOO-) in the cell.

Benefits of technology

FeTMPyP effectively alleviates nitrification stress caused by combined exposure of MC-LR and NaNO2, improves sex hormone disorders, erectile cycle disorders and follicle atresia, restores the fertility of mice, and has no obvious toxicity to mice at safe doses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120241742A_ABST
    Figure CN120241742A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicines, and particularly relates to application of FeTMPyP in preparation of a medicine for relieving ovarian toxicity. FeTMPyP is selected as an intervention agent aiming at the fact that MC-LR and NaNON combined exposure can remarkably induce mouse ovary nitration stress, mouse follicle barrier damage and ovarian reproductive endocrine dysfunction; the FeTMPyP can be used for effectively relieving nitration stress induced by combined exposure of MC-LR and NaNO2 in mouse ovaries, improving sex hormone disorder, disordered estrus cycle and follicular atresia phenomena caused by combined exposure of the two poisons, and recovering the fertility of the mouse, so that the intervention of the FeTMPyP can be used for relieving the mouse ovarian toxicity induced by combined exposure of MC-LR and NaNO2, and can be used for treating the ovarian toxicity of the mouse caused by combined exposure of the MC-LR and NaNO2. The compound can be used for preparing medicines for preventing and treating related diseases such as mouse ovarian toxicity caused by environmental toxin exposure, and a new way is provided for early recognition and targeted intervention of ovarian related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and particularly relates to a drug for alleviating ovarian toxicity. Background Art

[0002] Microcystins (MCs) are a class of cyclic heptapeptide intracellular toxins that widely exist in water bodies. They are intracellular toxins produced by a large number of cyanobacteria in eutrophic lakes and rivers. They can enter organisms through the food chain or direct contact, causing multi-organ damage. With the aggravation of water pollution, the health problems caused by environmental exposure to microcystins are becoming increasingly severe. Among the more than 200 MCs isomers that have been discovered, microcystin-LR (MC-LR) is the most abundant and toxic isomer. A large number of studies have shown that MC-LR has multi-organ toxicity and can accumulate in multiple tissues such as the liver, brain, ovary, intestine, and kidney of humans and animals, causing dysfunction of these systems. The gonad is its main target organ. Eutrophic water bodies also contain nitrite. As the most toxic inorganic nitrogen pollutant in water bodies, studies have shown that acute exposure to nitrite poses a toxic threat to the female reproductive system. Nitrite in water bodies mainly comes from domestic and industrial wastewater and the conversion of ammonia nitrogen in water bodies. It should be noted that ammonia nitrogen is also the main nutrient in water bodies, which can cause water eutrophication and the reproduction of algae, promoting the release of algal toxins in water. In eutrophic water bodies, the concentration of nitrite is usually positively correlated with the concentration of microcystins. MCs and nitrite often coexist in water bodies, and the two can significantly enhance the toxic effect through a synergistic effect, especially posing a serious threat to endocrine-sensitive organs (such as the ovary).

[0003] In recent years, the female reproductive toxicity caused by exposure to MCs and nitrite has received increasing attention. Epidemiological studies have found that the intake of nitrite is positively correlated with the risk of ovarian cancer in women. Microcystin exposure can cause programmed cell death of ovarian cells, reduce the number and quality of oocytes, and thus affect fertility. Existing studies mostly focus on the toxicity of single pollutants and lack a systematic analysis of the combined exposure mechanism. For example, traditional antioxidants (such as vitamin C, N-acetylcysteine) have a certain alleviating effect on single microcystin exposure (Xue Lijian, Li Jinhui, Yang Mingfeng, et al. Effects of combined exposure to N-acetylcysteine and microcystin-LR on apoptosis of Chinese hamster ovary cells [J]. Journal of Environment and Health, 2013, 30(10): 879-881.), but it is difficult to block the combined toxicity cascade reaction of MCs and nitrite.

[0004] Therefore, finding effective intervention measures to alleviate the female reproductive toxicity caused by exposure to MCs and nitrite is an important prevention and treatment strategy for alleviating ovarian-related diseases and protecting reproductive health. Summary of the Invention

[0005] To solve the problem of ovarian toxicity caused by the combined exposure of MCs and NaNO2, the present invention proposes an application of FeTMPyP in the preparation of a drug for relieving ovarian toxicity. Iron(III) meso-tetrakis(4-methylpyridyl)porphyrin (FeTMPyP) is selected as an intervention agent to target nitrative stress, providing a basis for new drug screening.

[0006] The technical solution of the present invention is realized as follows:

[0007] The combined exposure of MC-LR and NaNO2 can significantly induce nitrative stress in the ovaries of mice. Nitrative stress can change the structure and expression of proteins, leading to impaired cell function, which is the core mechanism of the combined exposure of the two toxins causing follicular barrier damage and ovarian reproductive endocrine dysfunction in mice. Therefore, nitrative stress can be used as a potential molecular biomarker for the ovarian toxicity caused by the combined exposure of microcystins and nitrites. Targeting nitrative stress and finding effective intervention measures are important prevention and treatment strategies for relieving ovarian-related diseases and protecting female reproductive health.

[0008] FeTMPyP is an ONOO−-decomposing catalyst with a special mechanism of action, showing the ability to precisely regulate the level of nitrative stress in the intracellular environment. In this application, BALB / c mice were used as the research object, and the nitrative stress inhibitor FeTMPyP was used for intervention. It was found that FeTMPyP in vivo could effectively relieve the nitrative stress induced by the combined exposure of MC-LR and NaNO2 in the ovaries of mice, and improve the sex hormone disorder, estrous cycle disorder and follicular atresia phenomenon caused by the combined exposure of these two toxins. At the same time, the fertility of mice was restored. It was further clarified that nitrative stress is the core mechanism of the combined exposure of the two toxins causing follicular barrier damage and ovarian reproductive endocrine dysfunction in mice. FeTMPyP can be used as a therapeutic agent for the ovarian toxicity caused by the exposure of MCs and nitrites, and can also be used to prepare drugs for preventing and treating diseases related to ovarian toxicity caused by environmental toxin exposure in mice. Targeting nitrative stress is an important prevention and treatment approach for relieving ovarian-related diseases and protecting female reproductive health.

[0009] Based on this, this application provides an application of FeTMPyP in the preparation of a drug for relieving ovarian toxicity.

[0010] Preferably, the above-mentioned ovarian toxicity is caused by environmental toxin exposure.

[0011] Preferably, the above-mentioned environmental toxin exposure is the combined exposure of MCs and NaNO2.

[0012] On the other hand, this application also proposes a drug for relieving ovarian toxicity, including FeTMPyP and a pharmaceutically acceptable carrier.

[0013] Preferably, the dosage of FeTMPyP in the above-mentioned drug is 10 mg / kg BW, and the action time of the drug is 3 months.

[0014] Preferably, the administration route of the above-mentioned drug is intraperitoneal injection once a week.

[0015] The alleviating effect of FeTMPyP on ovarian nitrative stress induced by the combined exposure of MC-LR and NaNO2 in BALB / c mice;

[0016] The alleviating effect of FeTMPyP on ovarian toxicity induced by the combined exposure of MC-LR and NaNO2;

[0017] Preferably, the above-mentioned ovarian toxicity is caused by environmental toxin exposure.

[0018] Preferably, the above-mentioned environmental toxin exposure is the combined exposure of MCs and NaNO2.

[0019] Furthermore, the diseases caused by the above-mentioned ovarian toxicity include damage to granulosa cell tight junctions, apoptosis, and disruption of the follicular barrier;

[0020] Furthermore, the diseases caused by the above-mentioned ovarian toxicity also include sex hormone disorders, estrous cycle disorders, follicular atresia, and adverse birth outcomes.

[0021] The present invention has the following beneficial effects:

[0022] 1. For the first time, in view of the disruption of the follicular barrier and ovarian reproductive endocrine dysfunction in mice caused by the combined exposure of MCs and NaNO2, FeTMPyP is selected as an intervention agent, and the alleviating effect and application of FeTMPyP in the ovarian toxicity of mice caused by the combined exposure of MCs and nitrite are provided, laying a foundation for new drug screening; different from traditional antioxidants or anti-inflammatory drugs, FeTMPyP specifically scavenges peroxynitrite (ONOO-) as an intervention target, clearly identifies nitrative stress as the core mechanism of ovarian toxicity caused by the combined exposure of MC-LR and NaNO2, has a clear molecular mechanism targeting, has the potential to be used as a disease intervention target, and will provide a new approach for the early identification and targeted intervention of ovarian-related diseases.

[0023] 2. The present application also conducts a safety assessment of FeTMPyP, indicating that FeTMPyP at a dose of 10 mg / kg BW and a treatment cycle of 3 months has no obvious systemic toxicity to mice and has good in vivo safety; FeTMPyP can effectively alleviate the nitrative stress induced by the combined exposure of MC-LR and NaNO2 in the ovaries of mice, improve the sex hormone imbalance, estrous cycle disorder, and follicular atresia phenomena caused by the combined exposure of these two toxins, reduce apoptosis and disruption of the follicular barrier, and at the same time restore the fertility of mice.

[0024] 3. This application expands the application field of FeTMPyP. FeTMPyP can be used as a therapeutic agent for the ovarian toxicity caused by the exposure to MCs and nitrite, and can also be used to prepare drugs for preventing and treating diseases such as ovarian toxicity in mice caused by environmental toxin exposure; it provides new ideas for the prevention and control of ovarian-related diseases caused by the combined exposure to MCs and nitrite, and enriches the theories and technologies for preventing and treating the poisoning effects of environmental toxins on human health. Description of the Drawings

[0025] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following will briefly introduce the drawings required for use in the description of the embodiments or the prior art. Obviously, the following drawings are only some embodiments of the present invention. For those of ordinary skill in the art, without creative efforts, other drawings can be obtained based on these drawings.

[0026] Figure 1 For the general toxicity assessment of FeTMPyP on mice; where A is the body weight change of mice, B is the liver index of mice, C is the kidney index, D is the heart index, E is the spleen index, and F is the ovarian index.

[0027] Figure 2 For FeTMPyP to relieve the disorder of sex hormone secretion in mice induced by the combined exposure to MC-LR and NaNO2; where A is the content of estradiol (E2), B is the content of follicle-stimulating hormone (FSH), C is the content of luteinizing hormone (LH), and D is the content of anti-Müllerian hormone (AMH).

[0028] Figure 3 For FeTMPyP to relieve the apoptosis of ovarian cells in mice induced by the combined exposure to MC-LR and NaNO2; where A is the expression level of apoptosis-related proteins detected by Western Blot in the ovarian tissues of mice, B is the quantitative analysis of the expression level of apoptosis-related proteins in the ovarian tissues of mice, C is the analysis of the apoptosis of ovarian cells in mice by TUNEL fluorescence staining, the blue fluorescence is the cell nucleus, and the green fluorescence is the apoptotic positive cells labeled by TUNEL.

[0029] Figure 4 For FeTMPyP to relieve the estrous cycle disorder in mice induced by the combined exposure to MC-LR and NaNO2; where A is the trend chart of the estrous cycle changes in experimental mice within 21 days, and B is the statistical analysis result of the estrous cycle of mice.

[0030] Figure 5 For FeTMPyP to relieve the follicular atresia in mice induced by the combined exposure to MC-LR and NaNO2; where A is the observation of the pathological histological changes and follicular development in the ovaries of mice by H&E staining, and B is the statistical analysis result of the follicle count in mice. Detailed implementation manners

[0031] The technical solutions of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts shall fall within the protection scope of the present invention.

[0032] Unless otherwise specified, the test methods used in the following experimental examples are all conventional methods; the materials, reagents, etc. used, unless otherwise specified, are reagents and materials that can be obtained from commercial channels.

[0033] For the first time, this application targets the destruction of the follicular barrier and ovarian reproductive endocrine dysfunction in mice caused by the combined exposure of MCs and NaNO2, selects FeTMPyP as an intervention agent, and provides the alleviating effect and application of FeTMPyP in the ovarian toxicity of mice caused by the combined exposure of MCs and nitrite, providing a basis for new drug screening; different from traditional antioxidants or anti-inflammatory drugs, targeting the specific scavenging of peroxynitrite (ONOO-) by FeTMPyP as an intervention target, it is clear that nitrative stress is the core mechanism of the combined exposure of MC-LR and NaNO2 causing ovarian toxicity, with a clear molecular mechanism targeting, and it has the potential to be a disease intervention target, which will provide a new way for the early recognition and targeted intervention of ovarian-related diseases, and also provide a new direction for the intervention of reproductive damage related to environmental toxicant exposure.

[0034] The combined exposure of MC-LR and NaNO2 can significantly induce nitrative stress in the ovaries of mice. Nitrative stress can change the structure and expression of proteins, leading to impaired cell function, which is the core mechanism of the combined exposure of the two toxins causing the destruction of the follicular barrier and ovarian reproductive endocrine dysfunction in mice. Therefore, nitrative stress can be used as a potential molecular biomarker for the ovarian toxicity caused by the combined exposure of microcystin and nitrite. Targeting nitrative stress and finding effective intervention measures are important prevention and treatment strategies for alleviating ovarian-related diseases and protecting female reproductive health.

[0035] FeTMPyP is an ONOO− decomposition catalyst with a special mechanism of action and shows the ability to precisely regulate the level of nitrative stress in the intracellular environment. In this application, BALB / c mice were used as the research subjects, and the nitrative stress inhibitor FeTMPyP was used for intervention. It was found that FeTMPyP intervention in vivo could effectively alleviate the nitrative stress induced by the combined exposure of MC-LR and NaNO2 in the mouse ovaries, improve the sex hormone disorder, estrous cycle disorder and follicular atresia caused by the combined exposure of these two toxins, and at the same time restore the fertility of the mice. It was further clarified that nitrative stress is the core mechanism of the combined exposure of the two toxins leading to the destruction of the follicular barrier and ovarian reproductive endocrine dysfunction in mice. FeTMPyP can be used as a therapeutic agent for the ovarian toxicity caused by the exposure of MCs and nitrite, and can also be used to prepare drugs for preventing and treating related diseases such as ovarian toxicity caused by environmental toxin exposure in mice. Targeting nitrative stress is an important prevention and treatment approach for alleviating ovarian-related diseases and protecting female reproductive health.

[0036] Materials and methods:

[0037] 1. Experimental reagents

[0038] Microcystin-LR (MC-LR, purity > 95%) was purchased from Beijing Apris Technology Development Co., Ltd.;

[0039] Sodium nitrite (NaNO2) was purchased from Shanghai Macklin Biochemical Co., Ltd.;

[0040] FeTMPyP was purchased from APExBIO Technology LLC, USA;

[0041] The cell apoptosis detection kit was purchased from Beijing Senbo Biotechnology Co., Ltd.;

[0042] The nitrite content detection kit, estradiol detection kit, follicle-stimulating hormone detection kit, luteinizing hormone detection kit, and anti-Müllerian hormone detection kit were purchased from Wuhan Elabscience Biotechnology Co., Ltd.;

[0043] Sodium pentobarbital was purchased from Merck, USA;

[0044] WB reagents were purchased from Jiangsu Kangwei Century Biotechnology Co., Ltd., and antibodies were purchased from Wuhan Sanying Biotechnology Co., Ltd.;

[0045] Other reagents were analytical grade reagents.

[0046] 2. Animal treatment

[0047] Three-week-old specific pathogen free (SPF) grade BALB / c female mice used in this experiment were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. and were housed in the barrier animal room of the School of Public Health, Zhengzhou University (SYXK(YU)2018-0005); all animal experiments have been approved by the Experimental Animal Ethics Committee of Zhengzhou University (Ethical number: ZZUIRB2023-023).

[0048] 3. Statistical analysis

[0049] The experimental data were expressed as mean ± standard deviation (SD). One-way analysis of variance (Analysis of Variance, Birmingham, UK) was used to analyze the significance of differences between groups, and then the Student-Newman-Keuls test was used. P < 0.05 was considered statistically significant. SPSS 21.0 (Armonk, NY, USA, 2012) was used to analyze the experimental data. GraphPad Prism 7 (Company, La Jolla, USA) was used to process the images.

[0050] Example 1: General toxicity assessment of FeTMPyP in mice

[0051] After one week of adaptive feeding of the mice, they were randomly divided into 2 groups, namely the control group and the FeP group. The mice in the control group freely drank distilled water; the mice in the FeP group were intervened by intraperitoneal injection with 10 mg / kg bw FeTMPyP once a week. The intervention time for the mice was 3 months.

[0052] The general toxic effects of FeTMPyP on mice were evaluated by changes in body weight and organ indices. The results showed that, as Figure 1 shown, after treating the mice with 10 mg / kg BW FeTMPyP for 3 months, there was no significant change in the body weight of the mice; further analysis of the organ indices of the mice found that there were no significant changes in the liver, kidney, heart, spleen, and ovary indices of the mice, indicating that the treatment with 10 mg / kg BW FeTMPyP had no toxic effect on the health of the mice.

[0053] Example 2: Study on the alleviating effect of FeTMPyP on ovarian toxicity in mice induced by combined exposure to MC-LR and NaNO2

[0054] After one week of adaptive feeding, the mice were randomly divided into 4 groups (see Table 1), namely the control group, M2N2 group, FeP group, and M2N2+FeP group. The mice in the control group were given distilled water to drink freely; the mice in the M2N2 group were co-exposed to MC-LR (100 μg / L) and NaNO2 (300 mg / L); the mice in the FeP group were treated with the nitration stress inhibitor FeTMPyP (10 mg / kg bw) by intraperitoneal injection once a week; the mice in the M2N2+FeP group were intervened with 10 mg / kg bw FeTMPyP during the co-exposure to MC-LR and NaNO2. The exposure and intervention time for the mice was 3 months.

[0055] Table 1 FeTMPyP intervention protocol during the exposure of mice to MC-LR and NaNO2

[0056]

[0057] After the exposure ended, 15 female mice from each group were caged with non-exposed male mice at a ratio of 1:1 to evaluate the fertility of the mice. During the euthanasia of the mice, they were anesthetized with 1% sodium pentobarbital, and then blood was collected from the artery. After euthanasia, the mice were quickly dissected, the ovarian tissues were separated and weighed, and then frozen in liquid nitrogen and stored in a -80 °C refrigerator. The collected whole blood was allowed to stand at room temperature for 2 h, and then centrifuged (3000 rpm, 4 °C, 20 min), and the upper serum was aspirated and stored in a -80 °C refrigerator.

[0058] 1. Detection of changes in sex hormones in mouse serum by ELISA

[0059] The concentrations of FSH, LH, and AMH in mouse serum were determined by double antibody sandwich ELISA. First, standard wells, blank wells, and sample wells were set up. 100 μL of serially diluted standards were added to the standard wells, and 100 μL of the serum samples to be tested were added to the remaining wells. The OD values of each well were measured using an enzyme-linked immunosorbent assay (ELISA) reader at a wavelength of 450 nm. The OD values of the samples were fitted to the standard curve, and combined with the known standard concentrations, the concentrations of FSH, LH, and AMH in mouse serum were calculated. Five mice from each group were used for the detection and analysis.

[0060] The level of E2 in mouse serum was detected by competitive ELISA. In the experiment, standard wells, blank wells, and sample wells were first set up. 50 μL of serially diluted standards were added to the standard wells, and 50 μL of the serum samples to be tested were added to the remaining wells. The OD values of each well were measured using an ELISA reader at a wavelength of 450 nm. The OD values of the samples were fitted to the standard curve, and combined with the known standard concentrations, the concentration of E2 in mouse serum was calculated. Five mice from each group were used for the detection and analysis.

[0061] by Figure 2It can be seen that the detection and analysis of sex hormone levels in mouse serum showed that compared with the control group, the combined exposure of 100 μg / L MC-LR and 300 mg / L NaNO2 significantly decreased the levels of E2 (about 35.7%), LH (about 41.9%) and AMH (about 47.6%), and increased the level of FSH (about 188%), with significant differences (P<0.05); while the intervention of 10 mg / kg BW FeTMPyP could significantly improve the decrease in E2 and AMH and the increase in FSH caused by the combined exposure of the two toxins (P<0.05; * indicates P<0.05, compared with the control group; # indicates P<0.05, compared with the M2N2 group). Compared with the M2N2 group, the levels of E2, AMH and FSH were restored by 46.9%, 96.2% and 43% respectively, indicating that FeTMPyP intervention could significantly relieve the sex hormone imbalance in mice caused by the combined exposure of MC-LR and NaNO2.

[0062] 2. Analysis of changes in the estrous cycle of mice by vaginal smear method

[0063] Use a pipette to aspirate 100 μL of normal saline, gently insert the pipette tip into the vagina of the mouse, slowly inject the normal saline, and then aspirate the vaginal secretions again with the pipette. Apply the collected secretions to an adhesive glass slide and let it dry naturally at room temperature. Subsequently, stain the smear with Wright-Giemsa stain for 2 min. Gently rinse the smear with distilled water to remove the excess dye. After the smear is completely dry, mount it with neutral gum and observe the cell morphology under a microscope. According to the different cell types in the smear, judge the stage of the estrous cycle of the mouse. Observe continuously for 14 days, record and analyze the changes in the estrous cycle of the mouse. 3 mice in each group were used for detection and analysis.

[0064] As Figure 4 shown, compared with the control group, the combined exposure of 100 μg / L MC-LR and 300 mg / L NaNO2 significantly shortened the duration of the estrus period of mice (shortened by about 50%), increased the duration of the diestrus period (increased by about 85.1%), and led to an extension of the estrous cycle (extended by about 85.1%) (P<0.05), while the FeTMPyP intervention could restore 33.4%, 28.1% and 34.5% respectively for the shortening of the estrus period, the increase in the diestrus period and the extension of the estrous cycle caused by the combined exposure of the two toxins (P<0.05). This indicates that FeTMPyP can effectively relieve the estrous cycle disorder in mice caused by the combined exposure of MC-LR and NaNO2.

[0065] 3. Observation of histological changes in mouse ovarian tissue by H&E staining

[0066] The mouse ovaries were collected rapidly, washed with cold PBS, fixed with 4% paraformaldehyde for 24 h, then equilibrated with 30% phosphate-buffered sucrose solution for 2 h, embedded in paraffin, and cut into 6-μm sections. The sections were dehydrated with xylene and 100% alcohol, stained with hematoxylin and eosin. Finally, the sections were observed and images were collected under a microscope to analyze the follicle development and pathological changes of ovarian tissue. Ovaries from 3 mice in each group were used for analysis.

[0067] Figure 5 A shows the pathological histological changes and follicle development of mouse ovaries observed by H&E staining (CL: corpus luteum, PF: primary follicle, SF: secondary follicle, GF: mature follicle, and AF: atretic follicle, the blue arrow indicates oocyte necrosis, fragmentation, and dissolution). Compared with the control group, in the groups exposed to MC-LR or NaNO2 alone and in combination, oocyte necrosis, fragmentation, and dissolution were observed after the combined exposure of 100 μg / L MC-LR and 300 mg / L NaNO2, accompanied by a significant increase in the number of atretic follicles (1.8-fold increase) (P < 0.05). However, the intervention with 10 mg / kg BW FeTMPyP decreased the number of atretic follicles increased by the combined exposure of the two toxins by 35.6% (P < 0.05). Figure 5 B) indicates that FeTMPyP treatment can be a potential intervention to alleviate the ovarian function damage caused by the combined exposure of MC-LR and NaNO2.

[0068] 4. Effects of FeTMPyP intervention on apoptosis of mouse ovarian cells induced by combined exposure of MC-LR and NaNO2

[0069] (1) TUNEL assay

[0070] Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) (Roche, Switzerland) was used to detect cell apoptosis. Briefly, the testes were fixed in 4% paraformaldehyde for 24 h, permeabilized with 0.1% Triton X-100, and washed twice. Then, the nucleotide mixture labeled with terminal deoxynucleotidyl transferase (TdT) was added to each slide and incubated at 37 °C for 1 h. Observation was carried out using a fluorescence microscope (Olympus, Tokyo, Japan) at an excitation of 488 nm and an emission of 530 nm. The labeled green fluorescent cell nuclei were selected as the unified standard for judging positive cells in all the photos using Image-Pro Plus 6.0 (Media Cybernetics, Inc., Rockville, MD, USA). The DAPI blue cell nuclei with the same marker were selected as the total cells. The apoptosis rate (%) was calculated as the number of positive cells / total cells × 100.

[0071] (2) Detection of the expression level of the target protein by Western Blot

[0072] Total protein extraction and concentration determination: Transfer an appropriate amount of mouse ovarian tissue to a 2 mL grinding tube, add 1 mL of pre-cooled RIPA lysis buffer (containing 1% protease inhibitor and 1% phosphatase inhibitor), grind on ice and then lyse for 30 min, with ultrasonic disruption performed every 10 min. After lysis, centrifuge the sample for 15 min (12000 rcf, 4 °C), collect the supernatant and transfer it to a new centrifuge tube. Determine the protein concentration using a BCA kit in combination with a multifunctional microplate reader. According to the measured protein concentration, adjust all samples to the same concentration using the lysis solution, add SDS-PAGE loading buffer, and boil at 100 °C for 10 min to denature the protein.

[0073] Western Blot experiment: Prepare the gel using a PAGE gel rapid preparation kit according to the standard procedure. Load 20 μg of protein into each gel well. After electrophoresis at a constant voltage of 60 V until the bromophenol blue enters the separating gel, change the voltage to 120 V until the bromophenol blue reaches the bottom of the gel. After electrophoresis, transfer the proteins on the gel to an ethanol-activated PVDF membrane by wet transfer method. The transfer conditions are 60 V and the transfer time is 120 min. After transfer, immerse the PVDF membrane in TBST containing 5% skim milk powder and shake at room temperature for 60 min for blocking. After blocking, dilute the primary antibody according to the antibody instruction manual and incubate overnight at 4 °C. The next day, wash the membrane 5 times with TBST buffer, 6 min each time, to remove the unbound primary antibody. Subsequently, add the HRP-labeled secondary antibody matching the primary antibody and incubate at room temperature for 1.5 h. Wash the membrane 5 times again with TBST, 6 min each time. Finally, develop the color using ECL chemiluminescence reagent to capture specific bands. Analyze the gray values of the bands of the target protein and the internal reference protein GAPDH using ImageJ software, and calculate the relative expression level of the target protein. Each experiment is performed with 3 independent replicates for statistical analysis.

[0074] It can be seen from Figure 3 that co-exposure to MC-LR and NaNO2 significantly increased the Bax / Bcl-2 ratio, as well as the levels of Cleaved Caspase-3 and Cleaved PARP in the mouse ovaries (P < 0.05), while FeTMPyP intervention significantly downregulated the levels of these apoptosis markers (P < 0.05). In addition, the results of immunofluorescence staining showed that after co-exposure to the two toxins, the proportion of apoptotic cells in the ovaries increased by 1.7-fold (P < 0.05); compared with the M2N2 group, after FeTMPyP intervention, the proportion of cell apoptosis decreased by approximately 65% (P < 0.05) ( Figure 3C and D). These results suggest that FeTMPyP intervention can alleviate apoptosis of mouse ovarian cells induced by combined exposure to MC-LR and NaNO2.

[0075] In summary, nitrative stress is the core mechanism of the combined exposure to MC-LR and NaNO2-induced ovarian toxicity in mice, and it has the potential to be a target for disease intervention. FeTMPyP intervention can effectively alleviate nitrative stress induced by the combined exposure to MC-LR and NaNO2 in the ovaries of mice, improve sex hormone disorders, estrous cycle disorders, and follicular atresia caused by the combined exposure to these two toxins, and at the same time restore the fertility of mice. FeTMPyP can be used as a therapeutic agent for ovarian toxicity caused by the exposure to MCs and nitrite, and can also be used to prepare drugs for preventing and treating related diseases such as ovarian toxicity caused by environmental toxin exposure in mice.

[0076] The above are only the preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of FeTMPyP in the preparation of a drug for relieving ovarian toxicity.

2. The application according to claim 1, wherein: The ovarian toxicity is caused by environmental toxin exposure.

3. The application according to claim 2, wherein: The environmental toxin exposure is the combined exposure of MCs and NaNO2.

4. A drug for relieving ovarian toxicity, characterized in that: It includes FeTMPyP and a pharmaceutically acceptable carrier.

5. The drug for alleviating ovarian toxicity according to claim 4, characterized in that: The dosage of FeTMPyP used in the drug is 10 mg / kg BW; the action time of the drug is 3 months.

6. The drug for alleviating ovarian toxicity according to claim 5, characterized in that: The administration route of the drug is intraperitoneal injection.

7. The drug for alleviating ovarian toxicity according to claim 6, wherein: The ovarian toxicity is caused by environmental toxin exposure.

8. The drug for alleviating ovarian toxicity according to claim 7, wherein: The environmental toxin exposure is the combined exposure of MCs and NaNO2.

9. The drug for alleviating ovarian toxicity according to claim 8, wherein: The diseases caused by the ovarian toxicity include sex hormone disorder, estrous cycle disorder, follicular atresia, and adverse birth outcomes.

10. The drug for alleviating ovarian toxicity according to claim 9, characterized in that: The diseases caused by the ovarian toxicity also include improvement of tight junction damage, apoptosis of granulosa cells, and destruction of follicular barrier.

Citation Information

Patent Citations

  • Method for determining microcystic toxins-LR in human urine through liquid chromatography-mass spectrometry

    CN118961934A

  • Application of iNOS inhibitor in preparation of medicine for relieving cell injury caused by toxin combined exposure

    CN120899741A

  • Application of inhibitor JSH-23 in preparation of medicine for preventing and / or treating ovarian toxicity caused by combined exposure of environmental toxins

    CN121041254A

  • Oxidized LDL as a biomarker for neurological complications of pregnancy

    US20140093517A1

  • Multifunctional Treatment And Diagnostic Compositions And Methods

    US20200121791A1

Cited By

  • Application of iNOS inhibitor in preparation of medicine for relieving cell injury caused by toxin combined exposure

    CN120899741A

  • Method for screening medicine for relieving reproductive toxicity of imidacloprid and application thereof

    CN120924634A

  • Application of inhibitor JSH-23 in preparation of medicine for preventing and / or treating ovarian toxicity caused by combined exposure of environmental toxins

    CN121041254A

  • The siRNA targeting vimentin and application thereof in preparing a drug for treating environmental toxicant-induced ovarian dysplasia

    CN122833023A